Cargando…

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation

Background: Congenital generalized lipodystrophy (CGL) is a rare inherited disease characterized by widespread loss of subcutaneous fat and severe metabolic abnormalities. Metreleptin, a synthetic analog of leptin, is a treatment modality that has been shown to decrease fasting triglycerides, fastin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schweisberger, Cintya, Jacobson, Jill Diane, Paprocki, Emily
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089820/ http://dx.doi.org/10.1210/jendso/bvab048.1429

Ejemplares similares

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

New advances in the treatment of generalized lipodystrophy: role of metreleptin
por: Rodriguez, Alexander J, et al.
Publicado: (2015)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Alterations in Lipid Signaling Underlie Lipodystrophy Secondary to AGPAT2 Mutations
por: Subauste, Angela R., et al.
Publicado: (2012)

Case report: Echocardiographic diagnosis of cardiac involvement caused by congenital generalized lipodystrophy in an infant
por: Zhou, Jie, et al.
Publicado: (2023)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

Leu124Serfs*26, a novel AGPAT2 mutation in congenital generalized lipodystrophy with early cardiovascular complications
por: Montenegro Junior, Renan Magalhães, et al.
Publicado: (2020)

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance
por: Lambadiari, Vaia, et al.
Publicado: (2021)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

LBODP083 Pharmacokinetics Of Metformin In Obese Non-diabetic Youth: Drug Clearance Increases With Severity Of Obesity
por: Halpin, Kelsee, et al.
Publicado: (2022)

PMON313 Hyperinsulinemic Hypoglycemia and Growth Hormone Deficiency Secondary to 20p11 Deletion
por: Wee, Erica, et al.
Publicado: (2022)

Identification of a novel nonsense mutation and a missense substitution in the AGPAT2 gene causing congenital generalized lipodystrophy type 1
por: Haghighi, Amirreza, et al.
Publicado: (2012)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

A Single Complex Agpat2 Allele in a Patient With Partial Lipodystrophy
por: Broekema, Marjoleine F., et al.
Publicado: (2018)

Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 2012;61:2922–2931
por: Subauste, AR, et al.
Publicado: (2013)

Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease
por: Ceccarini, Giovanni, et al.
Publicado: (2020)

Misdiagnosis of Paget’s Disease of Bone in a Congenital Generalized Lipodystrophy Patient: Case Report
por: Freire, Erika Bastos Lima, et al.
Publicado: (2021)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

Identification and Characterisation of a Novel Pathogenic Mutation in the Human Lipodystrophy Gene AGPAT2: C48R: A Novel Mutation in AGPAT2
por: Ramanathan, N., et al.
Publicado: (2012)

SAT-LB93 Rapid Reduction of Insulin Requirement in a Hyperglycemic Patient Treated for Hemophagocytic Lymphohistiocytosis
por: Schweisberger, Cintya, et al.
Publicado: (2020)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

Divergent Metabolic Phenotype between Two Sisters with Congenital Generalized Lipodystrophy Due to Double AGPAT2 Homozygous Mutations. A Clinical, Genetic and In Silico Study
por: Cortés, Víctor A., et al.
Publicado: (2014)

PSUN81 A novel case of congenital generalized lipodystrophy (CGL) with no genetic abnormalites in the AGPAT2, BSCL2, CAV1, and CAVIN1 genes.
por: Mericq, Veronica, et al.
Publicado: (2022)

SAT-291 Gonadotropin Releasing Hormone Agonist Therapy Improves Hyperandrogenism in an Adolescent with Type A Insulin Resistance Syndrome
por: Paprocki, Emily, et al.
Publicado: (2019)

ODP383 Clinical Presentation and Management of Diabetes Mellitus in Youth with Prader-Willi Syndrome
por: Paprocki, Emily, et al.
Publicado: (2022)

The acromegaly lipodystrophy
por: Freda, Pamela U.
Publicado: (2022)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

THU241 Novel PPARG Pathogenic Gene Variant In Newly Diagnosed Familial Partial Lipodystrophy With Childhood Onset
por: Chang, Eric K, et al.
Publicado: (2023)

THU229 Assessing The Effect Of The Changing Levels Of Restrictions Placed By The COVID-19 Pandemic On Children And Their Behaviors
por: Babar, Ghufran S, et al.
Publicado: (2023)

Cardiac Manifestations of Congenital Generalized Lipodystrophy
por: Sanon, Vani P., et al.
Publicado: (2016)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n4gjmdet0jas69m9ol8b1kcidn